Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 817, 86-95

The Gut-Brain Axis in Parkinson's Disease: Possibilities for Food-Based Therapies


The Gut-Brain Axis in Parkinson's Disease: Possibilities for Food-Based Therapies

Paula Perez-Pardo et al. Eur J Pharmacol.


Parkinson's disease (PD) is usually characterized by cardinal motor impairments. However, a range of non-motor symptoms precede the motor-phase and are major determinants for the quality of life. To date, no disease modifying treatment is available for PD patients. The gold standard therapy of levodopa is based on restoring dopaminergic neurotransmission, thereby alleviating motor symptoms, whereas non-motor symptoms remain undertreated. One of the most common non-motor symptoms is gastrointestinal dysfunction usually associated with alpha-synuclein accumulations and low-grade mucosal inflammation in the enteric nervous system. Accumulating evidence suggest that the enteric nervous system is involved in PD pathological progression towards the central nervous system. Moreover, different components of the gut could provide a central role in the gut-brain axis, which is as a bidirectional communicational system between the gastrointestinal tract and central nervous system. Dietary components might influence the gut-brain axis by altering microbiota composition or by affecting neuronal functioning in both the ENS and the CNS. This review gives a comprehensive overview of the evidences supporting the hypothesis that PD could initiate in the gut. We also consider how food-based therapies might then have an impact on PD pathology and/or improve non-motor as well as motor symptoms in PD.

Keywords: Alpha-synuclein; Enteric nervous system; Food-based therapies; Gastrointestinal dysfunction; Microbiota; Parkinson's disease.

Similar articles

  • Brain-gut-microbiota Axis in Parkinson's Disease
    A Mulak et al. World J Gastroenterol 21 (37), 10609-20. PMID 26457021. - Review
    Parkinson's disease (PD) is characterized by alpha-synucleinopathy that affects all levels of the brain-gut axis including the central, autonomic, and enteric nervous sys …
  • The Gut and Nonmotor Symptoms in Parkinson's Disease
    L Klingelhoefer et al. Int Rev Neurobiol 134, 787-809. PMID 28805583. - Review
    Gastrointestinal (GI) symptoms are one of the most common nonmotor symptoms (NMS) in patients with Parkinson's disease (PD) involving the whole GI tract (GIT) and being e …
  • Probiotics for Parkinson's Disease
    P Gazerani. Int J Mol Sci 20 (17). PMID 31450864. - Review
    Parkinson's disease (PD) is a complex neurological disorder classically characterized by impairments in motor system function associated with loss of dopaminergic neurons …
  • Microbiota-gut-brain Signalling in Parkinson's Disease: Implications for Non-Motor Symptoms
    VD Felice et al. Parkinsonism Relat Disord 27, 1-8. PMID 27013171. - Review
    Parkinson's disease is the second most common neurodegenerative disorder, affecting 1-2% of the population over 65 years of age. The primary neuropathology is the loss of …
  • Gut Dysfunction in Parkinson's Disease
    A Mukherjee et al. World J Gastroenterol 22 (25), 5742-52. PMID 27433087. - Review
    Early involvement of gut is observed in Parkinson's disease (PD) and symptoms such as constipation may precede motor symptoms. α-Synuclein pathology is extensively eviden …
See all similar articles

Cited by 22 PubMed Central articles

See all "Cited by" articles

LinkOut - more resources